ProBiotix Health Announces Major APAC Distribution Deal with Actial Farmaceutica for CholBiome®
OptiBiotix Health PLC (‘OptiBiotix’), a leading developer of compounds to tackle obesity, cardiovascular disease and diabetes, has announced its wholly-owned subsidiary – ProBiotix Health (‘ProBiotix’) – has partnered with a major Italian probiotics business, Actial Farmaceutica Srl (‘Actial’), for the distribution of CholBiome® and CholBiome®X3 in the Asia Pacific region.
The agreement grants Actial a non-exclusive licence to supply the cholesterol reducing supplement brand, CholBiome, to four new territories in the region, including Australia, New Zealand, Indonesia and Thailand.
Mikkel Hvid-Hansen, Commercial Director at ProBiotix, said: “The latest study from Imperial College London cites cholesterol levels are rising sharply across Asia, with nearly half of the 3.9 million worldwide deaths from high cholesterol occurring in East, South and Southeast Asia. Partnering with industry leader Actial to bring our CholBiome brand to the APAC region will help support greater heart health and reduce the risks associated with high cholesterol, such as cardiovascular disease.”
Backed by strong scientific principles, CholBiome and CholBiomeX3 feature the patented probiotic strain, Lactobacillus Plantarum LPLDL®, as their core ingredient. Results of a randomised, placebo-controlled, double-blind human intervention trial has shown that LPLDL reduces total cholesterol levels by up to 36.7%, lowers ‘bad’ low-density lipoprotein (LDL) cholesterol by 13.9% and increases ‘good’ high-density lipoprotein (HDL) cholesterol by 4.5%. In addition, the probiotic also decreases blood pressure by up to 5.1%.
The efficacy of LPLDL is enhanced further with CholBiomeX3. The dietary supplement features Monacolin K to prevent the buildup of cholesterol and Vitamin B3 to promote the reduction of LDL cholesterol, alongside the patented probiotic. This enables CholBiomeX3 to synergistically deliver a tri-factor approach that transforms the way physical health is managed.
“The expertise from Actial will be an asset to ProBiotix going forward,” adds Mikkel. “The company is known worldwide for its probiotic brand VSL#3®. As such, CholBiome and CholBiomeX3 will be marketed under this range to hospital clinicians, GPs and pharmacies as probiotic dietary food supplements, supporting the management of high cholesterol and blood pressure for patients in the region.”
With three subsidiaries worldwide, including CD Pharma India, Actial APAC and VSL Pharmaceuticals, Actial is focussed on the development of probiotic products. The company’s flagship product, VSL#3, is a probiotic blend of eight strains of lactic acid bacteria and bifidobacteria.
For more information on the latest news from OptiBiotix, please visit: https://optibiotix.com/